ABSTRACT
1. In rat aortic tissues pre-contracted with phenylephrine, certain 1,4-dihydropyridines (DHPs) such as Bay K 8644 (0.1 microM), PN 202791 (1 microM), RK 30 (1 microM), NI 104 (1 microM) and NI 105 (1 microM) enhanced photoactivated relaxations (photorelaxation or PR) whereas NI 72, NI 85, NI 99, NI 102, amlodipine, felodipine, nifedipine and nimodipine were inactive. 2. The PR inducing effects of Bay K 8644 were mimicked by the diabetogenic agent, streptozotocin (STZ). 3. Solutions of Bay K 8644 which had been irradiated for various periods of time initiated light independent transient relaxations followed by contractile responses in aortic tissue partially contracted with phenylephrine. With exposure times to light of 30 to 120 min, the intensity of the relaxation response to irradiated Bay K 8644 increased from 26 +/- 3.3 to 71 +/- 3.7% of the maximum contractile response to phenylephrine (n = 5). Conversely the contractile responses decreased, from 84.2 +/- 4.1 to 19.8 +/- 10.4% of the maximum contractile response to phenylephrine (n = 5). 4. Superoxide ions, generated by incubation of xanthine (2mM) plus xanthine oxidase (10 mu ml-1) in physiological saline solution (PSS) NaCl 118, KCl 4.7, CaCl2 2.5, KH2PO4 1.2, MgSO4 1.2, NaHCO3 12.5 and glucose 11.1 (mM) for 1 h. reduced the PR induced by DHPs, STZ, and also NO-induced relaxations of rat aortic preparations. 5. Direct measurements of NO indicate that, following exposure to a polychromatic light source, equimolar concentrations (0.1 mM) of the DHP compounds that enhance PR, as well as STZ, photodegrade to release NO (25 +/- 2-40.3 +/- 5.9 nmol min-1, n = 6). 6. Structure-activity studies indicate that a nitro group at the -3 position of the dihydropyridine ring is essential for DHPs to support PR. 7. These data suggest that the photodegradation of DHPs and STZ leading to the release of NO provides the primary cellular process underlying the PR response.
Subject(s)
3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester/pharmacology , Calcium Channel Agonists/pharmacology , Calcium Channel Blockers/pharmacology , Light , Muscle Relaxation/drug effects , Muscle Relaxation/radiation effects , Muscle, Smooth, Vascular/drug effects , Muscle, Smooth, Vascular/radiation effects , Nitric Oxide/metabolism , 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester/radiation effects , Animals , Anti-Bacterial Agents/pharmacology , Aorta, Thoracic/drug effects , Aorta, Thoracic/radiation effects , Calcium Channel Agonists/chemistry , Dose-Response Relationship, Drug , Muscle Tonus/drug effects , Muscle Tonus/radiation effects , Nitric Oxide/physiology , Photochemistry , Rats , Rats, Sprague-Dawley , Streptozocin/pharmacology , Structure-Activity RelationshipABSTRACT
We examined the production of nitric oxide (NO) from various nitro-containing compounds (500 microM and 100 microM solutions in Krebs buffer, pH 7.4). Sealed vials containing solutions of NaNO2, N-nitro-L-arginine, 4-nitrophenol, BAY K 8644, or N-nitro-L-arginine methyl ester were stored in the dark, under normal room light, or were exposed to ultraviolet light (365 nm), for 30 min (24 degrees C). NO was measured in the vial headspace after 30 min, using a sensitive assay previously established in our laboratory. Production of NO was found to be dependent on the intensity of light exposure for all compounds, and the highest degree of light-induced production of NO was found for NaNO2 and BAY K 8644 solutions. Since NO is a relaxant of smooth muscle, these results help explain the increased sensitivity to relaxation by UV light of vascular and other types of smooth muscle in the presence of NaNO2, BAY K 8644 and N-nitro-L-arginine, as observed by other investigators.
